source
- Solstice Oncology raises $225M Series A to push next-gen CTLA-4 antibody into Phase 2 colon cancer trialSolstice Oncology announced a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners and Forbion. The capital will fund the Phase 2 study of its Fc-e…
- ARPA-H selects UpDoc, Tempus AI and Atman Health for new AI heart-disease programARPA-H announced a new initiative called ADVOCATE that will bring together three companies to develop AI-driven tools for managing heart disease. The selected firms - UpDoc, Tempus AI, and Atman H…